Skip to Main Content

In the latest fallout from the EpiPen pricing scandal, Mylan (MYL) agreed to pay $30 million to settle charges by the Securities and Exchange Commission for failing to disclose to investors a Department of Justice probe into allegations of overcharging Medicaid for the allergy-relief device.

The settlement, which the company had indicated last July was being finalized, comes two years after the company paid $465 million for shortchanging the government health care program. At the time, the Justice Department had been investigating Mylan for knowingly classifying EpiPen as a generic product for nearly a decade in order to avoid paying the appropriate rebates owed to Medicaid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!